迈威生物靶向Nectin-4 ADC创新药9MW2821完成美国ADC经治三阴性乳腺癌临床试验首例患者给药

Core Viewpoint - Maiwei Biotech announced the completion of the first patient dosing in the clinical trial of its targeted Nectin-4 ADC innovative drug (code name: 9MW2821, generic name: Bulumtatug Fuvedotin) for patients with ADC-treated triple-negative breast cancer in the United States, marking a significant step in the globalization of its ADC portfolio [1] Company Summary - The clinical trial of 9MW2821 represents the first overseas clinical trial for the drug [1] - This development is a crucial milestone for Maiwei Biotech in the ADC field [1]